Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1225 to 1236 of 1259 entries
Sorted by: Best Match Show Resources per page
Characteristics and Prognosis of Colorectal Cancer after Liver or Kidney Transplantation.

World journal of surgery

Kim M, Kim CW, Hwang S, Kim YH, Lee JL, Yoon YS, Park IJ, Lim SB, Yu CS, Kim JC, Han DJ, Lee SG.
PMID: 34235562
World J Surg. 2021 Oct;45(10):3206-3213. doi: 10.1007/s00268-021-06219-9. Epub 2021 Jul 07.

BACKGROUND: The purpose of this study was to evaluate the characteristics and prognosis of de novo CRC patients who underwent liver or kidney transplantation.METHODS: We retrospectively reviewed the medical records of 66 de novo CRC patients selected from 8,734...

Cite
Kim M, Kim CW, Hwang S, et al. Characteristics and Prognosis of Colorectal Cancer after Liver or Kidney Transplantation. World J Surg. 2021;45(10):3206-3213doi: 10.1007/s00268-021-06219-9.
Kim, M., Kim, C. W., Hwang, S., Kim, Y. H., Lee, J. L., Yoon, Y. S., Park, I. J., Lim, S. B., Yu, C. S., Kim, J. C., Han, D. J., & Lee, S. G. (2021). Characteristics and Prognosis of Colorectal Cancer after Liver or Kidney Transplantation. World journal of surgery, 45(10), 3206-3213. https://doi.org/10.1007/s00268-021-06219-9
Kim, Minsung, et al. "Characteristics and Prognosis of Colorectal Cancer after Liver or Kidney Transplantation." World journal of surgery vol. 45,10 (2021): 3206-3213. doi: https://doi.org/10.1007/s00268-021-06219-9
Kim M, Kim CW, Hwang S, Kim YH, Lee JL, Yoon YS, Park IJ, Lim SB, Yu CS, Kim JC, Han DJ, Lee SG. Characteristics and Prognosis of Colorectal Cancer after Liver or Kidney Transplantation. World J Surg. 2021 Oct;45(10):3206-3213. doi: 10.1007/s00268-021-06219-9. Epub 2021 Jul 07. PMID: 34235562.
Copy Download .nbib Format: NLM
Nomogram to predict postoperative infectious complications after surgery for colorectal cancer: a retrospective cohort study in China.

World journal of surgical oncology

Wen J, Pan T, Yuan YC, Huang QS, Shen J.
PMID: 34238303
World J Surg Oncol. 2021 Jul 08;19(1):204. doi: 10.1186/s12957-021-02323-1.

BACKGROUND: Postoperative infectious complications (ICs) after surgery for colorectal cancer (CRC) increase in-hospital deaths and decrease long-term survival. However, the methodology for IC preoperative and intraoperative risk assessment has not yet been established. We aimed to construct a risk...

Cite
Wen J, Pan T, Yuan YC, et al. Nomogram to predict postoperative infectious complications after surgery for colorectal cancer: a retrospective cohort study in China. World J Surg Oncol. 2021;19(1):204doi: 10.1186/s12957-021-02323-1.
Wen, J., Pan, T., Yuan, Y. C., Huang, Q. S., & Shen, J. (2021). Nomogram to predict postoperative infectious complications after surgery for colorectal cancer: a retrospective cohort study in China. World journal of surgical oncology, 19(1), 204. https://doi.org/10.1186/s12957-021-02323-1
Wen, Jing, et al. "Nomogram to predict postoperative infectious complications after surgery for colorectal cancer: a retrospective cohort study in China." World journal of surgical oncology vol. 19,1 (2021): 204. doi: https://doi.org/10.1186/s12957-021-02323-1
Wen J, Pan T, Yuan YC, Huang QS, Shen J. Nomogram to predict postoperative infectious complications after surgery for colorectal cancer: a retrospective cohort study in China. World J Surg Oncol. 2021 Jul 08;19(1):204. doi: 10.1186/s12957-021-02323-1. PMID: 34238303; PMCID: PMC8268384.
Copy Download .nbib Format: NLM
Guillain-Barré syndrome.

Lancet (London, England)

Shahrizaila N, Lehmann HC, Kuwabara S.
PMID: 33647239
Lancet. 2021 Mar 27;397(10280):1214-1228. doi: 10.1016/S0140-6736(21)00517-1. Epub 2021 Feb 26.

Guillain-Barré syndrome is the most common cause of acute flaccid paralysis worldwide. Most patients present with an antecedent illness, most commonly upper respiratory tract infection, before the onset of progressive motor weakness. Several microorganisms have been associated with Guillain-Barré...

Cite
Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214-1228doi: 10.1016/S0140-6736(21)00517-1.
Shahrizaila, N., Lehmann, H. C., & Kuwabara, S. (2021). Guillain-Barré syndrome. Lancet (London, England), 397(10280), 1214-1228. https://doi.org/10.1016/S0140-6736(21)00517-1
Shahrizaila, Nortina, et al. "Guillain-Barré syndrome." Lancet (London, England) vol. 397,10280 (2021): 1214-1228. doi: https://doi.org/10.1016/S0140-6736(21)00517-1
Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021 Mar 27;397(10280):1214-1228. doi: 10.1016/S0140-6736(21)00517-1. Epub 2021 Feb 26. PMID: 33647239.
Copy Download .nbib Format: NLM
A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy.

Blood advances

Zhao P, Wu YJ, He Y, Chong S, Qu QY, Deng RX, Sun XW, Huang QS, Liu X, Zhu XL, Wang FR, Zhang YY, Mo XD, Han W, Wang JZ, Wang Y, Chen H, Chen YH, Zhao XY, Chang YJ, Xu LP, Liu KY, Huang XJ, Zhang XH.
PMID: 34507352
Blood Adv. 2021 Dec 28;5(24):5479-5489. doi: 10.1182/bloodadvances.2021004530.

Transplant-associated thrombotic microangiopathy (TA-TMA) is a potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Information on markers for early prognostication remains limited, and no predictive tools for TA-TMA are available. We attempted to develop and validate a...

Cite
Zhao P, Wu YJ, He Y, et al. A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. Blood Adv. 2021;5(24):5479-5489doi: 10.1182/bloodadvances.2021004530.
Zhao, P., Wu, Y. J., He, Y., Chong, S., Qu, Q. Y., Deng, R. X., Sun, X. W., Huang, Q. S., Liu, X., Zhu, X. L., Wang, F. R., Zhang, Y. Y., Mo, X. D., Han, W., Wang, J. Z., Wang, Y., Chen, H., Chen, Y. H., Zhao, X. Y., Chang, Y. J., Xu, L. P., Liu, K. Y., Huang, X. J., & Zhang, X. H. (2021). A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. Blood advances, 5(24), 5479-5489. https://doi.org/10.1182/bloodadvances.2021004530
Zhao, Peng, et al. "A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy." Blood advances vol. 5,24 (2021): 5479-5489. doi: https://doi.org/10.1182/bloodadvances.2021004530
Zhao P, Wu YJ, He Y, Chong S, Qu QY, Deng RX, Sun XW, Huang QS, Liu X, Zhu XL, Wang FR, Zhang YY, Mo XD, Han W, Wang JZ, Wang Y, Chen H, Chen YH, Zhao XY, Chang YJ, Xu LP, Liu KY, Huang XJ, Zhang XH. A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. Blood Adv. 2021 Dec 28;5(24):5479-5489. doi: 10.1182/bloodadvances.2021004530. PMID: 34507352; PMCID: PMC8714708.
Copy Download .nbib Format: NLM
Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0.

Radiographics : a review publication of the Radiological Society of North America, Inc

Chalian H, Töre HG, Horowitz JM, Salem R, Miller FH, Yaghmai V.
PMID: 22084190
Radiographics. 2011 Nov-Dec;31(7):2093-105. doi: 10.1148/rg.317115050.

Improvements in radiologic imaging technology and therapeutic options available for management of tumors have necessitated the revision of guidelines for the imaging-based assessment of tumor response to therapy. The purpose of this article is to familiarize radiologists with the...

Cite
Chalian H, Töre HG, Horowitz JM, et al. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. Radiographics. 2011;31(7):2093-105doi: 10.1148/rg.317115050.
Chalian, H., Töre, H. G., Horowitz, J. M., Salem, R., Miller, F. H., & Yaghmai, V. (2011). Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. Radiographics : a review publication of the Radiological Society of North America, Inc, 31(7), 2093-105. https://doi.org/10.1148/rg.317115050
Chalian, Hamid, et al. "Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0." Radiographics : a review publication of the Radiological Society of North America, Inc vol. 31,7 (2011): 2093-105. doi: https://doi.org/10.1148/rg.317115050
Chalian H, Töre HG, Horowitz JM, Salem R, Miller FH, Yaghmai V. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. Radiographics. 2011 Nov-Dec;31(7):2093-105. doi: 10.1148/rg.317115050. PMID: 22084190.
Copy Download .nbib Format: NLM
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).

ESMO open

Dano D, Lardy-Cleaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Ferrero JM, Guiu S, Campone M, de La Motte Rouge T, Petit T, Pistilli B, Dalenc F, Simon G, Lerebours F, Chabaud S, Bertucci F, Gonçalves A.
PMID: 34303929
ESMO Open. 2021 Aug;6(4):100220. doi: 10.1016/j.esmoop.2021.100220. Epub 2021 Jul 22.

BACKGROUND: Primary inflammatory breast cancer (IBC) is a rare and aggressive entity whose prognosis has been improved by multimodal therapy. However, 5-year overall survival (OS) remains poor. Given its low incidence, the prognosis of IBC at metastatic stage is...

Cite
Dano D, Lardy-Cleaud A, Monneur A, et al. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO Open. 2021;6(4):100220doi: 10.1016/j.esmoop.2021.100220.
Dano, D., Lardy-Cleaud, A., Monneur, A., Quenel-Tueux, N., Levy, C., Mouret-Reynier, M. A., Coudert, B., Mailliez, A., Ferrero, J. M., Guiu, S., Campone, M., de La Motte Rouge, T., Petit, T., Pistilli, B., Dalenc, F., Simon, G., Lerebours, F., Chabaud, S., Bertucci, F., & Gonçalves, A. (2021). Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO open, 6(4), 100220. https://doi.org/10.1016/j.esmoop.2021.100220
Dano, D, et al. "Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)." ESMO open vol. 6,4 (2021): 100220. doi: https://doi.org/10.1016/j.esmoop.2021.100220
Dano D, Lardy-Cleaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Ferrero JM, Guiu S, Campone M, de La Motte Rouge T, Petit T, Pistilli B, Dalenc F, Simon G, Lerebours F, Chabaud S, Bertucci F, Gonçalves A. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO Open. 2021 Aug;6(4):100220. doi: 10.1016/j.esmoop.2021.100220. Epub 2021 Jul 22. PMID: 34303929; PMCID: PMC8327489.
Copy Download .nbib Format: NLM
Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value.

Alimentary pharmacology & therapeutics

Black CJ, Yiannakou Y, Guthrie E, West R, Houghton LA, Ford AC.
PMID: 33705578
Aliment Pharmacol Ther. 2021 May;53(10):1126-1137. doi: 10.1111/apt.16322. Epub 2021 Mar 11.

BACKGROUND: Conventionally, irritable bowel syndrome (IBS) is subgrouped using predominant stool form, yet it is a complex disorder, with multiple biopsychosocial contributors. We previously derived and validated a latent class model subgrouping people with IBS into seven clusters based...

Cite
Black CJ, Yiannakou Y, Guthrie E, et al. Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. Aliment Pharmacol Ther. 2021;53(10):1126-1137doi: 10.1111/apt.16322.
Black, C. J., Yiannakou, Y., Guthrie, E., West, R., Houghton, L. A., & Ford, A. C. (2021). Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. Alimentary pharmacology & therapeutics, 53(10), 1126-1137. https://doi.org/10.1111/apt.16322
Black, Christopher J, et al. "Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value." Alimentary pharmacology & therapeutics vol. 53,10 (2021): 1126-1137. doi: https://doi.org/10.1111/apt.16322
Black CJ, Yiannakou Y, Guthrie E, West R, Houghton LA, Ford AC. Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. Aliment Pharmacol Ther. 2021 May;53(10):1126-1137. doi: 10.1111/apt.16322. Epub 2021 Mar 11. PMID: 33705578.
Copy Download .nbib Format: NLM
Idiopathic granulomatous lobular mastitis.

International journal of dermatology

Pereira FA, Mudgil AV, Macias ES, Karsif K.
PMID: 22250621
Int J Dermatol. 2012 Feb;51(2):142-51. doi: 10.1111/j.1365-4632.2011.05168.x.

Idiopathic granulomatous lobular mastitis (IGLM) is a rare breast condition with prominent skin findings. It is typically seen in young parous women. Painful breast masses, draining sinuses, scarring, and breast atrophy are the main clinical manifestations. IGLM can resemble...

Cite
Pereira FA, Mudgil AV, Macias ES, et al. Idiopathic granulomatous lobular mastitis. Int J Dermatol. 2012;51(2):142-51doi: 10.1111/j.1365-4632.2011.05168.x.
Pereira, F. A., Mudgil, A. V., Macias, E. S., & Karsif, K. (2012). Idiopathic granulomatous lobular mastitis. International journal of dermatology, 51(2), 142-51. https://doi.org/10.1111/j.1365-4632.2011.05168.x
Pereira, Frederick A, et al. "Idiopathic granulomatous lobular mastitis." International journal of dermatology vol. 51,2 (2012): 142-51. doi: https://doi.org/10.1111/j.1365-4632.2011.05168.x
Pereira FA, Mudgil AV, Macias ES, Karsif K. Idiopathic granulomatous lobular mastitis. Int J Dermatol. 2012 Feb;51(2):142-51. doi: 10.1111/j.1365-4632.2011.05168.x. PMID: 22250621.
Copy Download .nbib Format: NLM
A review of the AJCC melanoma staging system in the TNM classification (eighth edition).

Japanese journal of clinical oncology

Ogata D, Namikawa K, Takahashi A, Yamazaki N.
PMID: 33709104
Jpn J Clin Oncol. 2021 Apr 30;51(5):671-674. doi: 10.1093/jjco/hyab022.

In the eighth edition of the American Joint Committee on Cancer Staging Manual, several modifications were made for melanoma. These modifications were aimed at improving the prognosis prediction accuracy of the staging system. The main modifications are as follows:...

Cite
Ogata D, Namikawa K, Takahashi A, et al. A review of the AJCC melanoma staging system in the TNM classification (eighth edition). Jpn J Clin Oncol. 2021;51(5):671-674doi: 10.1093/jjco/hyab022.
Ogata, D., Namikawa, K., Takahashi, A., & Yamazaki, N. (2021). A review of the AJCC melanoma staging system in the TNM classification (eighth edition). Japanese journal of clinical oncology, 51(5), 671-674. https://doi.org/10.1093/jjco/hyab022
Ogata, Dai, et al. "A review of the AJCC melanoma staging system in the TNM classification (eighth edition)." Japanese journal of clinical oncology vol. 51,5 (2021): 671-674. doi: https://doi.org/10.1093/jjco/hyab022
Ogata D, Namikawa K, Takahashi A, Yamazaki N. A review of the AJCC melanoma staging system in the TNM classification (eighth edition). Jpn J Clin Oncol. 2021 Apr 30;51(5):671-674. doi: 10.1093/jjco/hyab022. PMID: 33709104.
Copy Download .nbib Format: NLM
Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using .

Japanese journal of radiology

Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, Tanemura A, Kanekura T, Yamazaki N, Ito K.
PMID: 34287739
Jpn J Radiol. 2022 Jan;40(1):75-85. doi: 10.1007/s11604-021-01174-w. Epub 2021 Jul 21.

OBJECTIVE: In malignant melanoma patients treated with immune checkpoint inhibitor (ICI) therapy, three different FDG-PET criteria, European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), immunotherapy-modified PERCIST (imPERCIST), were compared regarding response...

Cite
Kitajima K, Watabe T, Nakajo M, et al. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using . Jpn J Radiol. 2021;40(1):75-85doi: 10.1007/s11604-021-01174-w.
Kitajima, K., Watabe, T., Nakajo, M., Ishibashi, M., Daisaki, H., Soeda, F., Tanemura, A., Kanekura, T., Yamazaki, N., & Ito, K. (2022). Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using . Japanese journal of radiology, 40(1), 75-85. https://doi.org/10.1007/s11604-021-01174-w
Kitajima, Kazuhiro, et al. "Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using ." Japanese journal of radiology vol. 40,1 (2022): 75-85. doi: https://doi.org/10.1007/s11604-021-01174-w
Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, Tanemura A, Kanekura T, Yamazaki N, Ito K. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using . Jpn J Radiol. 2022 Jan;40(1):75-85. doi: 10.1007/s11604-021-01174-w. Epub 2021 Jul 21. PMID: 34287739.
Copy Download .nbib Format: NLM
Myocardial Perfusion and Viability Imaging in Coronary Artery Disease: Clinical Value in Diagnosis, Prognosis, and Therapeutic Guidance.

The American journal of medicine

Li DL, Kronenberg MW.
PMID: 33864764
Am J Med. 2021 Aug;134(8):968-975. doi: 10.1016/j.amjmed.2021.03.011. Epub 2021 Apr 20.

Coronary artery disease is a leading cause of morbidity and mortality worldwide. Noninvasive imaging tests play a significant role in diagnosing coronary artery disease, as well as risk stratification and guidance for revascularization. Myocardial perfusion imaging, including single photon...

Cite
Li DL, Kronenberg MW. Myocardial Perfusion and Viability Imaging in Coronary Artery Disease: Clinical Value in Diagnosis, Prognosis, and Therapeutic Guidance. Am J Med. 2021;134(8):968-975doi: 10.1016/j.amjmed.2021.03.011.
Li, D. L., & Kronenberg, M. W. (2021). Myocardial Perfusion and Viability Imaging in Coronary Artery Disease: Clinical Value in Diagnosis, Prognosis, and Therapeutic Guidance. The American journal of medicine, 134(8), 968-975. https://doi.org/10.1016/j.amjmed.2021.03.011
Li, Dan L, and Kronenberg, Marvin W. "Myocardial Perfusion and Viability Imaging in Coronary Artery Disease: Clinical Value in Diagnosis, Prognosis, and Therapeutic Guidance." The American journal of medicine vol. 134,8 (2021): 968-975. doi: https://doi.org/10.1016/j.amjmed.2021.03.011
Li DL, Kronenberg MW. Myocardial Perfusion and Viability Imaging in Coronary Artery Disease: Clinical Value in Diagnosis, Prognosis, and Therapeutic Guidance. Am J Med. 2021 Aug;134(8):968-975. doi: 10.1016/j.amjmed.2021.03.011. Epub 2021 Apr 20. PMID: 33864764.
Copy Download .nbib Format: NLM
A review of possible therapies for multiple sclerosis.

Molecular and cellular biochemistry

Li H, Lian G, Wang G, Yin Q, Su Z.
PMID: 33886059
Mol Cell Biochem. 2021 Sep;476(9):3261-3270. doi: 10.1007/s11010-021-04119-z. Epub 2021 Apr 22.

Multiple sclerosis (MS) is an autoimmune chronic inflammatory disease of the central nervous system with a wide range of symptoms, like executive function defect, cognitive dysfunction, blurred vision, decreased sensation, spasticity, fatigue, and other symptoms. This neurological disease is...

Cite
Li H, Lian G, Wang G, et al. A review of possible therapies for multiple sclerosis. Mol Cell Biochem. 2021;476(9):3261-3270doi: 10.1007/s11010-021-04119-z.
Li, H., Lian, G., Wang, G., Yin, Q., & Su, Z. (2021). A review of possible therapies for multiple sclerosis. Molecular and cellular biochemistry, 476(9), 3261-3270. https://doi.org/10.1007/s11010-021-04119-z
Li, Hui, et al. "A review of possible therapies for multiple sclerosis." Molecular and cellular biochemistry vol. 476,9 (2021): 3261-3270. doi: https://doi.org/10.1007/s11010-021-04119-z
Li H, Lian G, Wang G, Yin Q, Su Z. A review of possible therapies for multiple sclerosis. Mol Cell Biochem. 2021 Sep;476(9):3261-3270. doi: 10.1007/s11010-021-04119-z. Epub 2021 Apr 22. PMID: 33886059.
Copy Download .nbib Format: NLM
Showing 1225 to 1236 of 1259 entries